<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363805</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000487501</org_study_id>
    <secondary_id>U01CA101204</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>UARIZ-HSC-0353</secondary_id>
    <nct_id>NCT00363805</nct_id>
  </id_info>
  <brief_title>Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Chemoprevention of Lung Carcinogenesis Using Green Tea: Phase IIb Randomized, Double-Blinded, Placebo Controlled Trial of Green Tea and Polyphenon E in Former Smokers With Chronic Obstructive Lung Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherry Chow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming,
      growing, or coming back. The use of green tea or polyphenon E may prevent cancer from forming
      in former smokers with chronic obstructive pulmonary disease.

      PURPOSE: This randomized phase II trial is studying how well green tea or polyphenon E work
      in preventing lung cancer in former smokers with chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the effects of high-level oral consumption of defined green tea (four 12-oz
           servings/day) or polyphenon E capsules (4 capsules/day) on markers of cellular oxidative
           damage, as measured by 8-hydroxydeoxyguanosine (8-OHdG) and 8-F_2-isoprostanes
           (8-epi-PGF2) in former smokers with chronic obstructive pulmonary disease.

      Secondary

        -  Evaluate the effects of high-level oral consumption of defined green tea or polyphenon E
           capsules on body antioxidant status (carotenoids, vitamins A and E, ascorbic acid
           [vitamin C] and antioxidant enzymes [catalase and glutathione peroxidase]) in blood in
           these patients.

        -  Evaluate the effects of high-level oral consumption of defined green tea or polyphenon E
           capsules on gene expression of markers of proliferation and apoptosis in induced sputum
           in these patients.

      Tertiary

        -  Evaluate the effects of high-level oral consumption of defined green tea or polyphenon E
           capsules on lung function in these patients.

        -  Evaluate the relative adherence to use of green tea beverage vs polyphenon E capsules in
           these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
      stratified according to gender and inhaled steroid usage (yes vs no).

      All patients receive placebo tea beverage and placebo capsules 4 times a day for 2 weeks.
      Patients are randomized to 1 of 3 treatment arms after successful completion of the 2-week
      period.

        -  Arm I (green tea beverage): Patients receive oral green tea beverage and oral polyphenon
           E placebo daily for 6 months.

        -  Arm II (green tea capsule [polyphenon E]): Patients receive oral green tea beverage
           placebo and oral polyphenon E daily for 6 months.

        -  Arm III (placebo): Patients receive oral green tea beverage placebo and oral polyphenon
           E placebo daily for 6 months.

      Patients undergo blood, urine, exhaled breath condensate (EBC), induced sputum, and buccal
      cell collection at baseline and periodically during study for biomarker/laboratory analysis.
      Blood samples are analyzed for 8-hydroxydeoxyguanosine (8-OHdG), glutathione peroxidase, and
      catalase. Urine is examined for F_2-isoprostanes, 8-OHdG, and tea polyphenols. Induced sputum
      broncho-epithelial cells are analyzed for gene expression of genes implicated in cellular
      growth and apoptotic pathway via reverse transcriptase-polymerase chain reaction. EBC samples
      are examined for F_2-isoprostane levels. Buccal cells are stored for future analysis.

      PROJECTED ACCRUAL: A total of 195 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urinary 8-hydroxydeoxyguanosine Levels</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>the urinary concentrations of 8-hydroxydeoxyguanosine were normalized by the urinary creatinine concentrations to correct for variations in urine dilution/production and the change in urinary 8-hydroxydeoxyguanosine levels was calculated as the 6 months levels minus the baseline levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urinary 8-F2-isoprostanes Levels</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>the urinary concentrations of 8-F2-isoprostanes were normalized by the urinary creatinine concentrations to correct for variations in urine dilution/production and the change in urinary 8-F2-isoprostanes levels was calculated as 6 months levels minus baseline levels</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Lung Cancer Prevention</condition>
  <arm_group>
    <arm_group_label>Green Tea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive green tea beverage and placebo capsules for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyphenon E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo beverage and placebo capsules daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>green tea</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Green Tea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyphenon E</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Polyphenon E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic obstructive pulmonary disease

               -  FEV_1/FVC ≤ 78

          -  History of smoking ≥ 1 pack daily for 30 years OR 2 packs daily for 15 years

               -  Stopped smoking for ≥ 1 year

          -  No previously diagnosed bronchiectasis

          -  No history of &gt; 1 acute emphysema exacerbation within the past 3 months

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC ≥ 3,500/mm³

          -  Platelet count &gt; 130,000/mm³

          -  Hemoglobin ≥ 11 g/dL (female) or 12 g/dL (male)

          -  AST and ALT normal

          -  Bilirubin ≤ 1.5 mg/dL (unless Gilbert's disease present)

          -  Creatinine ≤ 1.5 mg/dL

          -  Alkaline phosphatase ≤ 2 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No invasive cancer within the past 5 years

          -  Able and willing to consume caffeinated beverages

          -  Able to produce induced sputum

          -  Able to perform forced expiratory maneuver during spirometry testing

          -  No immunosuppression by virtue of medication or disease including, but no limited to,
             any of the following:

               -  Organ transplantation

               -  Liver or kidney failure

               -  Autoimmune diseases

               -  Oral steroids

               -  Chemotherapy

          -  No serious concurrent illness that could preclude study compliance, such as
             uncontrolled high blood pressure, heart disease, or poorly controlled diabetes

          -  No myocardial infarction within the past 6 weeks

        PRIOR CONCURRENT THERAPY:

          -  At least 2 weeks since prior and no concurrent dietary supplements or herbal products,
             including any of the following:

               -  Herbal tea

               -  Ginkgo biloba &gt; 60 mg/day

               -  Melatonin &gt; 3 mg/day

               -  Echinacea &gt; 300 mg/day

               -  Hypericum perforatum (St. John's wort) &gt; 300 mg/day

               -  DHEA mustard &gt; 5 mg/day

          -  At least 2 weeks since prior and no concurrent nontrial tea or tea products

          -  More than 3 weeks since prior chest or abdominal surgery

          -  More than 3 months since prior participation in chemoprevention or clinical
             intervention trials

          -  At least 3 months since prior and no concurrent megadoses of vitamins, defined as &gt;
             4,000 IU of vitamin A, 400 IU of vitamin E, 400 IU of cholecalciferol (vitamin D), 60
             μg of selenium, or 1,000 mg of ascorbic acid (vitamin C) per day

          -  No regular consumption of ≥ 6 cups or glasses of tea per week

          -  No concurrent nontrial caffeine at &gt; 1 serving/day (1 serving defined as 12 oz of
             regular soda or 8 oz of coffee)

          -  No concurrent participation in another interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iman Hakim, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>July 2, 2013</results_first_submitted>
  <results_first_submitted_qc>September 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 28, 2013</results_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Sherry Chow</investigator_full_name>
    <investigator_title>Research Professor</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>prevention</keyword>
  <keyword>green tea</keyword>
  <keyword>former smokers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Green Tea</title>
          <description>Patients receive green tea beverage and placebo capsules for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Polyphenon E</title>
          <description>Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients receive placebo beverage and placebo capsules daily for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Green Tea</title>
          <description>Patients receive green tea beverage and placebo capsules for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Polyphenon E</title>
          <description>Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients receive placebo beverage and placebo capsules daily for 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="178"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.8" spread="9.2"/>
                    <measurement group_id="B2" value="63.6" spread="8.5"/>
                    <measurement group_id="B3" value="64.3" spread="7.8"/>
                    <measurement group_id="B4" value="64.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary 8-hydroxydeoxyguanosine Levels</title>
        <description>the urinary concentrations of 8-hydroxydeoxyguanosine were normalized by the urinary creatinine concentrations to correct for variations in urine dilution/production and the change in urinary 8-hydroxydeoxyguanosine levels was calculated as the 6 months levels minus the baseline levels</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>The number of participants analyzed was less than the number of participants completing the study because the analysis only included samples where the identify of the analyte was confirmed in the sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Green Tea</title>
            <description>Patients receive green tea beverage and placebo capsules for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Polyphenon E</title>
            <description>Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients receive placebo beverage and placebo capsules daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary 8-hydroxydeoxyguanosine Levels</title>
          <description>the urinary concentrations of 8-hydroxydeoxyguanosine were normalized by the urinary creatinine concentrations to correct for variations in urine dilution/production and the change in urinary 8-hydroxydeoxyguanosine levels was calculated as the 6 months levels minus the baseline levels</description>
          <population>The number of participants analyzed was less than the number of participants completing the study because the analysis only included samples where the identify of the analyte was confirmed in the sample.</population>
          <units>ng/mg creatinine</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="10.48"/>
                    <measurement group_id="O2" value="5.20" spread="36.20"/>
                    <measurement group_id="O3" value="-1.08" spread="25.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary 8-F2-isoprostanes Levels</title>
        <description>the urinary concentrations of 8-F2-isoprostanes were normalized by the urinary creatinine concentrations to correct for variations in urine dilution/production and the change in urinary 8-F2-isoprostanes levels was calculated as 6 months levels minus baseline levels</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>The number of participants analyzed was less than the number of participants completing the study because the analysis only included samples where the identity of the analyte was confirmed in the sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Green Tea</title>
            <description>Patients receive green tea beverage and placebo capsules for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Polyphenon E</title>
            <description>Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients receive placebo beverage and placebo capsules daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary 8-F2-isoprostanes Levels</title>
          <description>the urinary concentrations of 8-F2-isoprostanes were normalized by the urinary creatinine concentrations to correct for variations in urine dilution/production and the change in urinary 8-F2-isoprostanes levels was calculated as 6 months levels minus baseline levels</description>
          <population>The number of participants analyzed was less than the number of participants completing the study because the analysis only included samples where the identity of the analyte was confirmed in the sample.</population>
          <units>ng/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.87" spread="271.2"/>
                    <measurement group_id="O2" value="-35.80" spread="261.7"/>
                    <measurement group_id="O3" value="0.71" spread="266.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Green Tea</title>
          <description>Patients receive green tea beverage and placebo capsules for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Polyphenon E</title>
          <description>Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Patients receive placebo beverage and placebo capsules daily for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Other - blood clotting disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>pacemaker placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>other - pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>other - emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>other - knee surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Other - replacement of implant stimulator in abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Other - surgery for unclogging carotid artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Other - knee replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Other - placement of coronary stent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Other - surgery on right ankle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sherry Chow</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-626-3358</phone>
      <email>schow@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

